Aggressiveness niche: Can it be the foster ground for cancer metastasis precursors?

Stem Cells International

Volumn 2016, Issue , 2016, Pages

  Elshamy, Wael M ^a   Sinha, Abhilasha ^a   Said, Neveen ^b  

^a UNIVERSITY OF MISSISSIPPI MEDICAL CENTER   (United States)

^b WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AGGRESSIVENESS NICHE; CARCINOGENESIS; CELL DEATH; CELL FATE; CELL INTERACTION; CELL SURVIVAL; CELLULAR DISTRIBUTION; EPIGENETICS; HUMAN; HYPOXIA; IMMUNE DEFICIENCY; IMMUNE EVASION; INFLAMMATION; MESENCHYMAL STROMA CELL; METASTASIS; METASTASIS POTENTIAL; NEOPLASM; NONHUMAN; REVIEW; TUMOR ASSOCIATED LEUKOCYTE; TUMOR CELL; TUMOR GROWTH; TUMOR MICROENVIRONMENT;

EID: 84980010306     PISSN: None     EISSN: 16879678     Source Type: Journal    
DOI: 10.1155/2016/4829106     Document Type: Review

References (93)

1. D. Hanahan and R. A. Weinberg, "Thehallmarks of cancer," Cell, vol. 100, no. 1, pp. 57-70, 2000.
2. M. Luo, M. Brooks, and M. S. Wicha, "Epithelial-mesenchymal plasticity of breast cancer stem cells: implications formetastasis and therapeutic resistance," Current PharmaceuticalDesign, vol. 21, no. 10, pp. 1301-1310, 2015.
3. D. J. Drasin, T. P. Robin, and H. L. Ford, "Breast cancer epithelial-to-mesenchymal transition: examining the functional consequences of plasticity," Breast Cancer Research, vol. 13, no. 6, article 226, 2011.
4. B. Sangiuliano, N. M. Perez, D. F. Moreira, and J. E. Belizario, "Cell death-associatedmolecular-pattern molecules: inflammatory signaling and control," Mediators of Inflammation, vol. 2014, Article ID821043, 14 pages, 2014.
5. P. Scaffidi, T. Misteli, and M. E. Bianchi, "Release of chromatin protein HMGB1 by necrotic cells triggers inflammation," Nature, vol. 418, no. 6894, pp. 191-195, 2002.
6. D. Tang, R. Kang, K. M. Livesey et al., "Endogenous HMGB1 regulates autophagy," Journal of Cell Biology, vol. 190, no. 5, pp. 881-892, 2010.
7. S. Ananthula, A. Sinha, M. E. Gassim et al., "Geminin overexpression-dependent recruitment and crosstalk withmesenchymal stem cells enhance aggressiveness in triple negative breast cancers," Oncotarget, 2016.
8. F. Wu, Z.-H. Zhao, S.-T. Ding, H.-H. Wu, and J.-J. Lu, "High mobility group box 1 protein is methylated and transported to cytoplasm in clear cell renal cell carcinoma," Asian Pacific Journal of Cancer Prevention, vol. 14,no. 10,pp. 5789-5795, 2013.
9. Y. H. Kim, M. S. Kwak, J. B. Park et al., "N-linked glycosylation plays a crucial role in the secretion of HMGB1," Journal of Cell Science, vol. 129, no. 1, pp. 29-38, 2016.
10. K. Davis, S. Banerjee, A. Friggeri, C. Bell, E. Abraham, and M. Zerfaoui, "Poly(ADP-Ribosyl)ation of high mobility group box 1 (HMGB1) protein enhances inhibition of efferocytosis," Molecular Medicine, vol. 18, no. 3, pp. 359-369, 2012.
11. I. Ugrinova, E. A. Pasheva, J. Armengaud, and I. G. Pashev, "In vivo acetylation of HMG1 protein enhances its binding affinity to distorted DNA structures," Biochemistry, vol. 40, no. 48, pp. 14655-14660, 2001.
12. R. Kang, D. Tang, N. E. Schapiro et al., "The HMGB1/RAGE inflammatory pathway promotes pancreatic tumor growth by regulating mitochondrial bioenergetics," Oncogene, vol. 33, no. 5, pp. 567-577, 2014.
13. M. T. Lotze and K. J. Tracey, "High-mobility group box 1 protein (HMGB1): nuclear weapon in the immune arsenal," Nature Reviews Immunology, vol. 5, no. 4, pp. 331-342, 2005.
14. D. Tang, R. Kang, C. B. Coyne, H. J. Zeh, and M. T. Lotze, "PAMPs and DAMPs: signal 0s that spur autophagy and immunity," Immunological Reviews, vol. 249, no. 1, pp. 158-175, 2012.
15. H. Yang, H. S. Hreggvidsdottir, K. Palmblad et al., "A critical cysteine is required for HMGB1 binding to toll-like receptor 4 and activation of macrophage cytokine release," Proceedings of the National Academy of Sciences of the United States of America, vol. 107, no. 26, pp. 11942-11947, 2010.
16. C. Gebhardt, A. Riehl, M. Durchdewald et al., "RAGE signaling sustains inflammation and promotes tumor development," The Journal of Experimental Medicine, vol. 205, no. 2, pp. 275-285, 2008.
17. L. Campana, L. Bosurgi, and P. Rovere-Querini, "HMGB1: a two-headed signal regulating tumor progression and immunity," CurrentOpinion in Immunology, vol. 20,no. 5, pp. 518-523, 2008.
18. A. Taguchi, D. C. Blood, G. del Toro et al., "Blockade of RAGE-amphoterin signalling suppresses tumour growth and metastases," Nature, vol. 405, no. 6784, pp. 354-360, 2000.
19. J. Heijmans, N. V. J. A. Buller, E. Hoff et al., "Rage signalling promotes intestinal tumourigenesis," Oncogene, vol. 32, no. 9, pp. 1202-1206, 2013.
20. R. Kang, T. Loux, D. Tang et al., "The expression of the receptor for advanced glycation endproducts (RAGE) is permissive for early pancreatic neoplasia," Proceedings of theNational Academy of Sciences of the United States of America, vol. 109, no. 18, pp. 7031-7036, 2012.
21. H. Kuniyasu, N. Oue, A. Wakikawa et al., "Expression of receptors for advanced glycation end-products (RAGE) is closely associated with the invasive and metastatic activity of gastric cancer," The Journal of Pathology, vol. 196, no. 2, pp. 163-170, 2002.
22. T. Sasahira, Y. Akama, K. Fujii, and H. Kuniyasu, "Expression of receptor for advanced glycation end products and HMGB1/amphoterin in colorectal adenomas," Virchows Archiv, vol. 446, no. 4, pp. 411-415, 2005.
23. A. Tsung, R. Sahai, H. Tanaka et al., "The nuclear factor HMGB1 mediates hepatic injury after murine liver ischemiareperfusion," Journal of Experimental Medicine, vol. 201, no. 7, pp. 1135-1143, 2005.
24. D. G. Perregaux, P. McNiff, R. Laliberte, M. Conklyn, and C. A. Gabel, "ATP acts as an agonist to promote stimulusinduced secretion of IL-1β and IL-18 in human blood," Journal of Immunology, vol. 165, no. 8, pp. 4615-4623, 2000.
25. L. Agostini, F. Martinon, K. Burns, M. F. McDermott, P. N. Hawkins, and J. Tschopp, "NALP3 forms an IL-1β-processing inflammasome with increased activity in Muckle-Wells autoinflammatory disorder," Immunity, vol. 20, no. 3, pp. 319-325, 2004.
26. M. Gattorno, S. Tassi, S. Carta et al., "Pattern of interleukin-1β secretion in response to lipopolysaccharide and ATP before and after interleukin-1 blockade in patients with CIAS1 mutations," Arthritis and Rheumatism, vol. 56, no. 9, pp. 3138-3148, 2007.
27. G. Kroemer, L. Galluzzi, O. Kepp, and L. Zitvogel, "Immunogenic cell death in cancer therapy," Annual Review of Immunology, vol. 31, pp. 51-72, 2013.
28. H.M. Hoffman, J. L. Mueller, D. H. Broide, A. A. Wanderer, and R. D. Kolodner, "Mutation of a new gene encoding a putative pyrin-like protein causes familial cold autoinflammatory syndrome and Muckle-Wells syndrome," Nature Genetics, vol. 29, no. 3, pp. 301-305, 2001.
29. M. Okamoto, W. Liu, Y. Luo et al., "Constitutively active inflammasome in human melanoma cells mediating autoinflammation via caspase-1 processing and secretion of interleukin-1β," The Journal of Biological Chemistry, vol. 285, no. 9, pp. 6477-6488, 2010.
30. G. Sollberger, G. E. Strittmatter, M. Garstkiewicz, J. Sand, and H.-D. Beer, "Caspase-1: the inflammasome and beyond," Innate Immunity, vol. 20, no. 2, pp. 115-125, 2014.
31. A. Kusume, T. Sasahira, Y. Luo et al., "Suppression of dendritic cells by HMGB1 is associated with lymph node metastasis of human colon cancer," Pathobiology, vol. 76, no. 4, pp. 155-162, 2009.
32. Z. Liu, L. D. Falo Jr., and Z. You, "Knockdown of HMGB1 in tumor cells attenuates their ability to induce regulatory T cells and uncovers naturally acquired CD8 T cell-dependent antitumor immunity," The Journal of Immunology, vol. 187, no. 1, pp. 118-125, 2011.
33. Y. He, J. Zha, Y. Wang, W. Liu, X. Yang, and P. Yu, "Tissue damage-associated danger signals influence T-cell responses that promote the progression of preneoplasia to cancer," Cancer Research, vol. 73, no. 2, pp. 629-639, 2013.
34. M. Elkabets, V. S. G. Ribeiro, C. A. Dinarello et al., "IL-1β regulates a novel myeloid-derived suppressor cell subset that impairs NK cell development and function," European Journal of Immunology, vol. 40, no. 12, pp. 3347-3357, 2010.
35. S. K. Bunt, V. K. Clements, E. M. Hanson, P. Sinha, and S. Ostrand-Rosenberg, "Inflammation enhances myeloid-derived suppressor cell cross-talk by signaling through Toll-like receptor 4," Journal of Leukocyte Biology, vol. 85, no. 6, pp. 996-1004, 2009.
36. C. A. Dinarello and J. W. M. van der Meer, "Treating inflammation by blocking interleukin-1 in humans," Seminars in Immunology, vol. 25, no. 6, pp. 469-484, 2013.
37. M. Tafani, L. Schito, L. Pellegrini et al., "Hypoxia-increased RAGE and P2X7R expression regulates tumor cell invasion through phosphorylation of Erk1/2 and Akt and nuclear translocation of NF-κB," Carcinogenesis, vol. 32, no. 8, pp. 1167-1175, 2011.
38. W. Yan, Y. Chang, X. Liang et al., "High-mobility group box 1 activates caspase-1 and promotes hepatocellular carcinoma invasiveness and metastases," Hepatology, vol. 55, no. 6, pp. 1863-1875, 2012.
39. P. J. Ratcliffe, "HIF-1 and HIF-2: working alone or together in hypoxia?"The Journal of Clinical Investigation, vol. 117, no. 4, pp. 862-865, 2007.
40. R. K. Bruick, "Oxygen sensing in the hypoxic response pathway: regulation of the hypoxia-inducible transcription factor," Genes and Development, vol. 17, no. 21, pp. 2614-2623, 2003.
41. C. J. Schofield and P. J. Ratcliffe, "Oxygen sensing by HIF hydroxylases," Nature ReviewsMolecular Cell Biology, vol. 5, no. 5, pp. 343-354, 2004.
42. R. H. Wenger, D. P. Stiehl, and G. Camenisch, "Integration of oxygen signaling at the consensus HRE," Sciences STKE, vol. 2005, no. 306, article re12, 2005.
43. C. J. Fox, P. S. Hammerman, and C. B. Thompson, "Fuel feeds function: energy metabolism and the T-cell response," Nature Reviews Immunology, vol. 5, no. 11, pp. 844-852, 2005.
44. D. J. Kominsky, E. L. Campbell, and S. P. Colgan, "Metabolic shifts in immunity and inflammation," Journal of Immunology, vol. 184, no. 8, pp. 4062-4068, 2010.
45. V. Nizet and R. S. Johnson, "Interdependence of hypoxic and innate immune responses," Nature Reviews Immunology, vol. 9, no. 9, pp. 609-617, 2009.
46. C. T. Taylor and S. P. Colgan, "Hypoxia and gastrointestinal disease," Journal of MolecularMedicine, vol. 85, no. 12, pp. 1295-1300, 2007.
47. Y. Makino, H. Nakamura, E. Ikeda et al., "Hypoxia-inducible factor regulates survival of antigen receptor-driven T cells," The Journal of Immunology, vol. 171, no. 12, pp. 6534-6540, 2003.
48. H. Nakamura, Y. Makino, K. Okamoto et al., "TCR engagement increases hypoxia-inducible factor-1α protein synthesis via rapamycin-sensitive pathway under hypoxic conditions in human peripheral T cells,"The Journal of Immunology, vol. 174, no. 12, pp. 7592-7599, 2005.
49. M. Sitkovsky and D. Lukashev, "Regulation of immune cells by local-tissue oxygen tension: HIF1α and adenosine receptors," Nature Reviews Immunology, vol. 5, no. 9, pp. 712-721, 2005.
50. A. K. Neumann, J. Yang, M. P. Biju et al., "Hypoxia inducible factor 1α regulates T cell receptor signal transduction," Proceedings of the National Academy of Sciences of the United States of America, vol. 102, no. 47, pp. 17071-17076, 2005.
51. F. Sotgia, U. E. Martinez-Outschoorn, S. Pavlides, A. Howell, R. G. Pestell, and M. P. Lisanti, "Understanding theWarburg effect and the prognostic value of stromal caveolin-1 as a marker of a lethal tumor microenvironment," Breast Cancer Research, vol. 13, no. 4, article 213, 2011.
52. Z. Husain, Y. Huang, P. Seth, and V. P. Sukhatme, "Tumorderived lactate modifies antitumor immune response: effect on myeloid-derived suppressor cells and NK cells," The Journal of Immunology, vol. 191, no. 3, pp. 1486-1495, 2013.
53. S. C. Mendes, C. Robin, and E. Dzierzak, "Mesenchymal progenitor cells localize within hematopoietic sites throughout ontogeny," Development, vol. 132, no. 5, pp. 1127-1136, 2005.
54. V. Sordi, M. L. Malosio, F. Marchesi et al., "Bone marrow mesenchymal stem cells express a restricted set of functionally active chemokine receptors capable of promoting migration to pancreatic islets," Blood, vol. 106, no. 2, pp. 419-427, 2005.
55. A. Giordano, U. Galderisi, and I. R. Marino, "From the laboratory bench to the patients bedside: an update on clinical trials with mesenchymal stem cells," Journal of Cellular Physiology, vol. 211, no. 1, pp. 27-35, 2007.
56. M. Studeny, F. C. Marini, J. L. Dembinski et al., "Mesenchymal stem cells: potential precursors for tumor stroma and targeteddelivery vehicles for anticancer agents," Journal of the National Cancer Institute, vol. 96, no. 21, pp. 1593-1603, 2004.
57. S. C. Picinich, P. J. Mishra, P. J. Mishra, J. Glod, and D. Banerjee, "The therapeutic potential of mesenchymal stem cells," Expert Opinion on Biological Therapy, vol. 7, no. 7, pp. 965-973, 2007.
58. M. F. Pittenger, A. M. Mackay, S. C. Beck et al., "Multilineage potential of adult human mesenchymal stem cells," Science, vol. 284, no. 5411, pp. 143-147, 1999.
59. M. J. Bissell and D. Radisky, "Putting tumours in context," Nature Reviews Cancer, vol. 1, no. 1, pp. 46-54, 2001.
60. A. Orimo, P. B. Gupta, D. C. Sgroi et al., "Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion," Cell, vol. 121, no. 3, pp. 335-348, 2005.
61. N. C. Direkze, K. Hodivala-Dilke, R. Jeffery et al., "Bone marrow contribution to tumor-associated myofibroblasts and fibroblasts," Cancer Research, vol. 64, no. 23, pp. 8492-8495, 2004.
62. P. J. Mishra, P. J. Mishra, R. Humeniuk et al., "Carcinomaassociated fibroblast-like differentiation of human mesenchymal stem cells," Cancer Research, vol. 68, no. 11, pp. 4331-4339, 2008.
63. E. L. Spaeth, J. L. Dembinski, A. K. Sasser et al., "Mesenchymal stem cell transition to tumor-associated fibroblasts contributes to fibrovascular network expansion and tumor progression," PLoS ONE, vol. 4, no. 4,Article ID e4992, 2009.
64. J. L. Spees, S. D. Olson, J. Ylostalo et al., "Differentiation, cell fusion, and nuclear fusion during ex vivo repair of epitheliumby human adult stemcells from bonemarrow stroma," Proceedings of the National Academy of Sciences of the United States of America, vol. 100, no. 5, pp. 2397-2402, 2003.
65. S. A. Kuznetsov, P. H. Krebsbach, K. Satomura et al., "Singlecolony derived strains of human marrow stromal fibroblasts form bone after transplantation in vivo," Journal of Bone and Mineral Research, vol. 12, no. 9, pp. 1335-1347, 1997.
66. D. J. Prockop, C. A. Gregory, and J. L. Spees, "One strategy for cell and gene therapy: harnessing the power of adult stemcells to repair tissues," Proceedings of the National Academy of Sciences of the United States of America, vol. 100, supplement 1, pp. 11917-11923, 2003.
67. A. E. Karnoub, A. B. Dash, A. P. Vo et al., "Mesenchymal stem cells within tumour stroma promote breast cancer metastasis," Nature, vol. 449, no. 7162, pp. 557-563, 2007.
68. A. Y. Khakoo, S. Pati, S. A. Anderson et al., "Human mesenchymal stem cells exert potent antitumorigenic effects in a model of Kaposis sarcoma,"The Journal of ExperimentalMedicine, vol. 203, no. 5, pp. 1235-1247, 2006.
69. P. A. Toste, A. H. Nguyen, B. E. Kadera et al., "Chemotherapyinduced inflammatory gene signature and protumorigenic phenotype in pancreatic CAFs via stress-associated MAPK," Molecular Cancer Research, vol. 14, no. 5, pp. 437-447, 2016.
70. H. F. Dvorak, "Tumors: wounds that do not heal," The New England Journal of Medicine, vol. 315, no. 26, pp. 1650-1659, 1986.
71. R. M. Dwyer, S. M. Potter-Beirne, K. A. Harrington et al., "Monocyte chemotactic protein-1 secreted by primary breast tumors stimulates migration of mesenchymal stem cells," Clinical Cancer Research, vol. 13, no. 17, pp. 5020-5027, 2007.
72. S.-Y. Lin, J. Yang, A. D. Everett et al., "The isolation of novel mesenchymal stromal cell chemotactic factors from the conditioned medium of tumor cells," Experimental Cell Research, vol. 314, no. 17, pp. 3107-3117, 2008.
73. Y. Rattigan, J.-M. Hsu, P. J. Mishra, J. Glod, and D. Banerjee, "Interleukin 6mediated recruitment of mesenchymal stem cells to the hypoxic tumor milieu," Experimental Cell Research, vol. 316, no. 20, pp. 3417-3424, 2010.
74. K. E. Hatzistergos, H. Quevedo, B. N. Oskouei et al., "Bone marrow mesenchymal stem cells stimulate cardiac stem cell proliferation and differentiation," Circulation Research, vol. 107, no. 7, pp. 913-922, 2010.
75. J. M. Sorrell and A. I. Caplan, "Topical delivery ofmesenchymal stem cells and their function inwounds," StemCell Research and Therapy, vol. 1, no. 4, article 30, 2010.
76. F. Djouad, P. Plence, C. Bony et al., "Immunosuppressive effect of mesenchymal stem cells favors tumor growth in allogeneic animals," Blood, vol. 102, no. 10, pp. 3837-3844, 2003.
77. F. Djouad, C. Bony, F. Apparailly, P. Louis-Plence, C. Jorgensen, and D. Noel, "Earlier onset of syngeneic tumors in the presence of mesenchymal stem cells," Transplantation, vol. 82, no. 8, pp. 1060-1066, 2006.
78. A. Corcione, F. Benvenuto, E. Ferretti et al., "Humanmesenchymal stem cells modulate B-cell functions," Blood, vol. 107, no. 1, pp. 367-372, 2006.
79. W. Deng, Q. Han, L. Liao, S. You, H. Deng, and R. C.H. Zhao, "Effects of allogeneic bone marrow-derived mesenchymal stem cells on T and B lymphocytes from BXSB mice," DNA and Cell Biology, vol. 24, no. 7, pp. 458-463, 2005.
80. M. Di Nicola, C. Carlo-Stella, M. Magni et al., "Human bone marrow stromal cells suppress T-lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli," Blood, vol. 99, no. 10, pp. 3838-3843, 2002.
81. S. Glennie, I. Soeiro, P. J. Dyson, E. W.-F. Lam, and F. Dazzi, "Bone marrow mesenchymal stem cells induce division arrest anergy of activated T cells," Blood, vol. 105, no. 7, pp. 2821-2827, 2005.
82. M. Sioud, A. Mobergslien, A. Boudabous, and Y. Floisand, "Evidence for the involvement of galectin-3 in mesenchymal stem cell suppression of allogeneic T-cell proliferation," Scandinavian Journal of Immunology, vol. 71, no. 4, pp. 267-274, 2010.
83. M. Dominici, K. Le Blanc, I. Mueller et al., "Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement," Cytotherapy, vol. 8, no. 4, pp. 315-317, 2006.
84. V. D. Roobrouck, F. Ulloa-Montoya, and C. M. Verfaillie, "Selfrenewal and differentiation capacity of young and aged stem cells, " Experimental Cell Research, vol. 314, no. 9, pp. 1937-1944, 2008.
85. F. Djouad, L.-M. Charbonnier, C. Bouffi et al., "Mesenchymal stem cells inhibit the differentiation of dendritic cells through an interleukin-6-dependentmechanism," STEMCELLS, vol. 25, no. 8, pp. 2025-2032, 2007.
86. X.-X. Jiang, Y. Zhang, B. Liu et al., "Human mesenchymal stem cells inhibit differentiation and function of monocyte-derived dendritic cells," Blood, vol. 105, no. 10, pp. 4120-4126, 2005.
87. R. Ramasamy, H. Fazekasova, E. W.-F. Lam, I. Soeiro, G. Lombardi, and F. Dazzi, "Mesenchymal stem cells inhibit dendritic cell differentiation and function by preventing entry into the cell cycle," Transplantation, vol. 83, no. 1, pp. 71-76, 2007.
88. S. Gordon and P. R. Taylor, "Monocyte and macrophage heterogeneity," Nature Reviews Immunology, vol. 5, no. 12, pp. 953-964, 2005.
89. C. E. Lewis, R. Leek, A. Harris, and J. O. McGee, "Cytokine regulation of angiogenesis in breast cancer: the role of tumorassociated macrophages," Journal of Leukocyte Biology, vol. 57, no. 5, pp. 747-751, 1995.
90. D. M. Mosser, "The many faces of macrophage activation," Journal of Leukocyte Biology, vol. 73, no. 2, pp. 209-212, 2003.
91. G. Solinas, G. Germano, A. Mantovani, and P. Allavena, "Tumor-associatedmacrophages (TAM) as major players of the cancer-related inflammation," Journal of Leukocyte Biology, vol. 86, no. 5, pp. 1065-1073, 2009.
92. L. Turner, C. Scotton, R. Negus, and F. Balkwill, "Hypoxia inhibits macrophage migration," European Journal of Immunology, vol. 29, no. 7, pp. 2280-2287, 1999.
93. F. A. W. Verreck, T. De Boer, D. M. L. Langenberg et al., "Human IL-23-producing type 1 macrophages promote but IL-10-producing type 2 macrophages subvert immunity to (myco)bacteria," Proceedings of the National Academy of Sciences of the United States of America, vol. 101, no. 13, pp. 4560-4565, 2004.